Journal of Interferon & Cytokine Research · 1998 · 30 citations · 26 references
Life SciencesImmunologyOncologyApoptosisMolecular OncologyTumor ImmunologyApoptosis In CancerApoptosis RegulationApoptotic SignalingB Cell BiologyBcl-2 Family ProteinsApoptotic MorphologyApoptotic ResponseB Cell ApoptosisBcl-xl FunctionCell Survival AssaysG1 Phase ProgressionG1-s Phase TransitionPro-apoptotic Bax Activation
Although interferon-alpha (IFN-alpha) has proved beneficial in the treatment of some tumors, the basis for this is still uncertain. In this study, we examined the effects of IFN-alpha on the growth of tumor cells in vitro, using the Daudi line of B lymphoma cells as a model. There was a dose-dependent accumulation of these cells in the G1 phase of the cell cycle 24-48 h from the time of exposure to IFN-alpha. This was followed between 48 h and 96 h by an increasing degree of apoptosis, as assessed by cell survival, propidium iodine staining, and transmission electron microscopy. Concomitantly with the apoptosis, there was the appearance of pl8 Bax-alpha, an apparently novel variant low molecular weight form of the p21 Bax-alpha found in normal cells. There was also a slight diminution in Bcl-xL, with a resultant drop in the Bcl-xL:Bax-alpha ratio. Treatment of cells with CD40-L partially inhibited the development of apoptosis in response to IFN-alpha. At the same time, generation of p18 Bax-alpha was reduced, which suggests that this plays a part in the apoptotic process. These findings may throw light on the development of lymphomas and perhaps point to future ways of improving therapy with IFN-alpha.
26
Bax-Deficient Mice with Lymphoid Hyperplasia and Male Germ Cell Death
C. Michael Knudson, Kenneth S. K. Tung, Warren G. Tourtellotte et al. · Science · 1995 · 1.5K citations
Conversion of Bcl-2 to a Bax-like Death Effector by Caspases
Emily H. Cheng, David G. Kirsch, Rollie J. Clem et al. · Science · 1997 · 1.1K citations